Our Story: Accelerating Solid Targetry for Medical Isotopes

In 2007 & 2009 there was a widespread shortage of technetium-99m

(99mTc) - an isotope used in more than 40 million nuclear medicine scans around the world every year due to reactor outages of the precursor isotope, which caused significant price increases, delayed and canceled medical procedures,
all resulting in a substantial decline in patient quality of care.

In response ARTMS developed first-to-market,

locally deployable method for producing 99mTc using existing, hospital-based medical cyclotrons to tackle the supply chain issues. In addition to 99mTc, we have developed advanced solutions for the supply of Gallium-68 (68Ga), Zirconium-89 (89Zr) and Copper-64 (64Cu).

ARTMS holds the exclusive global commercialization rights to award-winning and proprietary Canadian inventions

which address these challenges, and which offer the prospect of revolutionizing the nuclear medicine industry.

Our Partners

Global Customers

Global map of QIS customers